Radius Health Inc. buy melinda
Start price
11.09.18
/
50%
€17.03
Target price
18.10.18
€18.85
Performance (%)
4.29%
End price
18.10.18
€17.76
Summary
This prediction ended on 18.10.18 with a price of €17.76. The BUY prediction by melinda finished with a performance of 4.29%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Radius Health Inc. | - | - | - | - |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by melinda for this prediction
In the thread Radius Health Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 13/09 | 19:30 Présentation
Develops drug therapies for the treatment of osteoporosis and other women's health conditions
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology.
The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.
The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology.
The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.
The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
Nombre d'employés : 561 personnes.
Stopped prediction by melinda for Radius Health Inc.
Radius Health Inc.
Start price
Target price
Perf. (%)
€25.93
08.11.17
08.11.17
€36.08
29.12.17
29.12.17
13.06%
29.12.17
29.12.17
Radius Health Inc.
Start price
Target price
Perf. (%)
€28.75
08.11.17
08.11.17
€40.00
29.12.17
29.12.17
13.06%
29.12.17
29.12.17
Radius Health Inc.
Start price
Target price
Perf. (%)
€41.39
21.02.17
21.02.17
€66.75
21.08.17
21.08.17
-22.60%
21.08.17
21.08.17
Radius Health Inc.
Start price
Target price
Perf. (%)
€38.23
27.01.17
27.01.17
€40.59
14.02.17
14.02.17
6.51%
14.02.17
14.02.17
Radius Health Inc.
Start price
Target price
Perf. (%)
€30.70
10.05.16
10.05.16
€33.37
01.06.16
01.06.16
8.79%
01.06.16
01.06.16